Tuesday 30 September 2014

Metabolic effects of thrombin on cultured skeletal muscle cells



Institute Research Student Seminars

Speakers:  Ali Al-Bayati & Paul Simon Banks


Venue: Seminar room L2.5, 2nd floor, William Leech Building, Medical School

Date and time:  Wednesday 1st October 2014 at 12.30


Paul Simon Banks will be providing a discussion




Ali Al-Bayati will present:


"The metabolic effects of thrombin on cultured skeletal muscle cells"


We try to explore the effect of thrombin on insulin signalling and glucose uptake in human skeletal muscle cells in culture, and the possible role of thrombin in insulin resistance and Diabetes.



Key words: thrombin, skeletal muscle, insulin signalling



Chair:  Anna-Lena Dittrich









Monday 22 September 2014

Immunology NE Seminar 2nd October 2014 Chronic Granulomatous Disease




We are very pleased to announce that next month's guest is Dr Frank van de Veerdonk, from the The Radboud University Medical Center  in Nijmegen, The Netherlands http://www.rimls.nl/themes/infectious-diseases-and-host-response, to talk on:


"Unravelling the ROS paradox in chronic granulomatous disease"


At 5pm on Thursday, October 2nd, 2014 in room 2.21, Research Beehive, Newcastle University (refreshments will be available from 4.30 pm).


Franks main research interests are the mechanisms responsible for Th17 defects in patients with Hyper-IgE (HIES) and chronic mucocutaneous candidiasis (CMC). His research also focuses on host defense against aspergillus infections, and patients with chronic granolumatous disease (CGD).

The other main focus is cytokine biology with a specific interest for the interleukin-1 family of cytokines where in collaboration with Charles Dinarello, the effects of new IL‑1 family members (IL-36,IL-37 and IL-38) are being investigated for their effects in host defence against fungal infection including Th17 responses.

Franks work has been recognized by prizes including International Cytokine Society Award, Outstanding Scholar Award, the ICAAC award for young investigator in 2013 and participation in the 60th Nobel Laureate Meeting in Lindau. 


If you would like to speak to Frank during his visit please contact desa.lilic@ncl.ac.uk


Some of Franks recent publications can be  found here:


de Luca, A. et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. PNAS 2014



Gresnigt, M. S. et al. A polysaccharide virulence factor from Aspergillus fumigatus elicits anti-inflammatory effects through induction of Interleukin-1 receptor antagonist. PLoS pathogens 2014



Gow, N. A. R., van de Veerdonk, F. L., Brown, A. J. P. & Netea, M. G. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nature Reviews Microbiology (2012)



van de Veerdonk, F. L. et al. STAT1 Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis. New England Journal of Medicine (2011)



van de Veerdonk, F. L. et al. The Macrophage Mannose Receptor Induces IL-17 in Response to Candida albicans. Cell host & microbe (2009)





Friday 19 September 2014

Mathematical Modelling and Patient Stratification - Monday 22 September



Monday 22 September @ 3.30 pm

Room 2.21 Research Beehive


Professor Walter Kolch

Director of Systems Biology Ireland & Conway Institute

University College Dublin


Walter Kolch is Director of Systems Biology Ireland and the Conway Institute at University College Dublin (Ireland). Trained as an MD he worked in experimental clinical research, the pharmaceutical industry, and basic biological research. He is best known for his work in oncogene signal transduction, proteomics and systems biology. His current research interest focuses on understanding how biochemical networks specify biological decisions, and how systems biology approaches can help clinical advances.  Prof Kolch will introduce a select number of projects aimed at a general (non-specialist) audience and therefore I strongly encourage attendance to what promises to be a really exciting seminar.


"Using mathematical pathway modelling for patient stratification"


Signalling pathways exert finely tuned control over cell fate decisions that ultimately determine the behaviour of cancer cells. It could therefore be expected that the dynamics of key pathway activation may contain prognostically relevant information over and above that which is contained in the static expression levels of individual biomarkers. To investigate this hypothesis we have characterised the network architecture that regulates JNK stress signalling in neuroblastoma cells and applied a modelling approach to extract prognostic information from neuroblastoma patient-specific simulations of JNK activation. Our experimental analysis identified a stress induced, ultrasensitive mode of JNK activation facilitated by positive feedback from JNK to its upstream kinase MKK7, which was constrained by inhibitory crosstalk from Akt and further regulated through scaffolding by the MAP3K ZAK. We then utilised an experimentally calibrated and validated mathematical model of this network structure to simulate patient-specific JNK network responses for 369 neuroblastoma patients. Survival analysis based upon the dynamics of these responses revealed that an inability to initiate switch-like JNK signalling in silico was significantly associated with decreased survival for both MYCN amplified and non-amplified neuroblastoma patients.


Faculty contacts: 

Mauro Santibanez-Koref (mauro.santibanez-koref@newcastle.ac.uk)

Diego Miranda-Saavedra (diego.miranda-saavedra@ncl.ac.uk)

Sponsored by: Scientific Laboratory Supplies








Thursday 18 September 2014

Gene Therapy for Type 2 Diabetes




Institute Research Student Seminars

Speakers:  Gillian Patterson & Shameem Ladak


Venue: Seminar room L2.2, 2nd floor, William Leech Building, Medical School

Date and time:  Wednesday 24th September 2014 at 3.00pm


Gillian Patterson will present:


“Incretin-based muscle-targeted gene therapy for type 2 diabetes”


Evaluating plasmid and AAV-mediated GLP1 (and its long-acting homologue Exendin 4) gene therapy in normal and diabetic mice. Constitutively active plasmid vectors were injected into both anterior tibialis and gastrocnemius muscles in CD1 or db/db mice, with adjuvant hyaluronidase pre-treatment and electroporation. AAV vectors were injected as described, without the pre-treatment. Both vector systems gave varying and unexpected results.



Key words: Diabetes, gene therapy, GLP1



Shameem Ladak will discuss:


Identification of biomarkers of bronchiolitis Obliterans Syndrome (BOS) for predicting early loss of lung graft function”


Post lung transplant chronic lung allograft rejection continues to be a problem despite enhancement in surgical techniques. Early identification of developing graft dysfunction is critical before changes in lung structure are evident as this stage transplant injury is likely to be irreversible. Most studies identify a single biomarker but we believe a combination of biomarkers could give better predictive value. This would be important as it would allow accurate prediction of the risk of graft rejection and would therefore reduce the risk of morbidity and preserve graft function.


Key words:      Lung transplant, BOS, biomarkers


Chair:  Sophie Cassidy






Friday 12 September 2014

Cell Signalling and Immune Response Regulation

We are very pleased to announce that this month's guest is Dr Simon Arthur  from the College of Life Sciences, University of Dundee.  http://www.lifesci.dundee.ac.uk/people/simon-arthur


Simon will be giving a presentation entitled: "Intra-cellular signalling pathways in the regulation of immune responses"


5pm next Thursday, September 18th 2014 in room 2.21, Research Beehive, Newcastle University (Refreshments will be available from 4.30 pm).


The interests of the Arthur laboratory lie in signalling networks that control inflammation, with a  particular focus on the roles that cells of the innate immune system play in coordinating inflammation and how they contribute to activation of adaptive immunity via the production of cytokines.



If you would like to speak to Simon during his visit please contact Graeme O'Boyle: Graeme.O'Boyle@sunderland.ac.uk





Some of Simons' recent publications can be found here:


Transcriptional regulation of IL-10 and its cell-specific role in vivo. 2014  Crit Rev Immunol. MacKenzie KF, Pattison MJ, Arthur JS. http://www.ncbi.nlm.nih.gov/pubmed/24941159



The catalytic subunit of the system L1 amino acid transporter (slc7a5) facilitates nutrient signalling in mouse skeletal muscle. PLoS One. 2014 Poncet N, Mitchell FE, Ibrahim AF, McGuire VA, English G, Arthur JS, Shi YB, Taylor PM. http://www.ncbi.nlm.nih.gov/pubmed/24586861



CREB phosphorylation at Ser133 regulates transcription via distinct mechanisms downstream of cAMP and MAPK signalling. 2014 Biochem J.  Naqvi S, Martin KJ1, Arthur JS. http://www.ncbi.nlm.nih.gov/pubmed/24438093



Cooperative control of holliday junction resolution and DNA repair by the SLX1 and MUS81-EME1 nucleases. Mol Cell. 2013 Castor D, Nair N, Déclais AC, Lachaud C, Toth R, Macartney TJ, Lilley DM, Arthur JS, Rouse J. http://www.ncbi.nlm.nih.gov/pubmed/24076219



Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. Proc Natl Acad Sci U S A. 2013  Emmerich CH, Ordureau A, Strickson S, Arthur JS, Pedrioli PG, Komander D, Cohen P. http://www.ncbi.nlm.nih.gov/pubmed/23986494



Cross talk between the Akt and p38α pathways in macrophages downstream of Toll-like receptor signaling. Mol Cell Biol. 2013 McGuire VA, Gray A, Monk CE, Santos SG, Lee K, Aubareda A, Crowe J, Ronkina N, Schwermann J, Batty IH, Leslie NR, Dean JL, O'Keefe SJ, Boothby M, Gaestel M, Arthur JS. http://www.ncbi.nlm.nih.gov/pubmed/23979601



Mitogen-activated protein kinases in innate immunity. 2013 Nat Rev Immunol Arthur JS, Ley SC. http://www.ncbi.nlm.nih.gov/pubmed/23954936




Dr Rachel Harry



Thursday 11 September 2014

Osteoarthritis Research Symposium, Tynemouth, September 2014

Tim Cawston and friends at the Osteoarthritis Symposium, Tynemouth, September 10th 2014.  

Tuesday 9 September 2014

Bioinformatics Seminar - Dr Alex Bateman - non-coding RNAs

Dr Alex Bateman from the European Bioinformatics Institute (EMBL-EBI) will present a seminar on Tuesday 9 September at 2pm in Beehive 2.21, entitled:


"RNAcentral: A new comprehensive resource of non-coding RNAs."



Dr Alex Bateman leads the the Protein sequence resources cluster that includes world leading databases including UniProt, Pfam, Rfam, TreeFam and MEROPS. As Head of Protein Sequence Resources at EMBL-EBI, Alex Bateman also has an important strategic leadership role in the InterPro and UniProtKB databases.


The host for this seminar is Phillip Lord (Bioinformatics, Computing Science)


' A novel mechanism for stopping inflammation - lessons from an ''old disease'' ' Professor Georg Schett








Guest Speaker: Professor Georg Schett

Institute for Clinical Immunology

University Erlangen-Nuremberg, Germany


Venue: David Shaw Lecture Theatre, Medical School


Date and time:  Tuesday 23rd September 2014 at 1.00pm


Professor Schett will discuss:


A novel mechanism for stopping inflammation - lessons from an “old disease”



2014 publications are below:


1.            Avouac J, Palumbo-Zerr K, Ruzehaji N, Tomcik M, Zerr P, Dees C, Distler A, Beyer C, Schneider H, Distler O et al: The nuclear receptor CAR / NR1I3 enhances the pro-fibrotic effects of TGF-beta and contributes to the development of experimental dermal fibrosis. Arthritis & rheumatology (Hoboken, NJ) 2014.

2.            Beyer C, Huang J, Beer J, Zhang Y, Palumbo-Zerr K, Zerr P, Distler A, Dees C, Maier C, Munoz L et al: Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Annals of the rheumatic diseases 2014.

3.            Beyer C, Zampetaki A, Lin NY, Kleyer A, Perricone C, Iagnocco A, Distler A, Langley SR, Gelse K, Sesselmann S et al: Signature of circulating microRNAs in osteoarthritis. Annals of the rheumatic diseases 2014.

4.            Beyer C, Zenzmaier C, Palumbo-Zerr K, Mancuso R, Distler A, Dees C, Zerr P, Huang J, Maier C, Pachowsky ML et al: Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling. Annals of the rheumatic diseases 2014.

5.            Boyle DL, Hammaker D, Edgar M, Zaiss MM, Teufel S, David JP, Schett G, Firestein GS: Differential roles of MAPK kinases MKK3 and MKK6 in osteoclastogenesis and bone loss. PloS one 2014, 9(1):e84818.

6.            Bozec A, Zaiss MM, Kagwiria R, Voll R, Rauh M, Chen Z, Mueller-Schmucker S, Kroczek RA, Heinzerling L, Moser M et al: T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Science translational medicine 2014, 6(235):235ra260.

7.            Conaghan PG, Kloppenburg M, Schett G, Bijlsma JW: Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee. Annals of the rheumatic diseases 2014, 73(8):1442-1445.

8.            D'Agostino MA, Boers M, Kirwan J, van der Heijde D, Ostergaard M, Schett G, Landewe RB, Maksymowych WP, Naredo E, Dougados M et al: Updating the OMERACT filter: implications for imaging and soluble biomarkers. The Journal of rheumatology 2014, 41(5):1016-1024.

9.            Dees C, Schlottmann I, Funke R, Distler A, Palumbo-Zerr K, Zerr P, Lin NY, Beyer C, Distler O, Schett G et al: The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Annals of the rheumatic diseases 2014, 73(6):1232-1239.

10.          Derer A, Groetsch B, Harre U, Bohm C, Towne J, Schett G, Frey S, Hueber AJ: Blockade of IL-36 Receptor Signaling Does Not Prevent from TNF-Induced Arthritis. PloS one 2014, 9(8):e101954.

11.          Distler A, Lang V, Del Vecchio T, Huang J, Zhang Y, Beyer C, Lin NY, Palumbo-Zerr K, Distler O, Schett G et al: Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Annals of the rheumatic diseases 2014, 73(6):1264-1268.

12.          Distler A, Ziemer C, Beyer C, Lin NY, Chen CW, Palumbo-Zerr K, Dees C, Weidemann A, Distler O, Schett G et al: Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. Annals of the rheumatic diseases 2014, 73(3):624-627.

13.          Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O et al: Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Annals of the rheumatic diseases 2014, 73(5):803-809.

14.          Finzel S, Sahinbegovic E, Ernet C, Kocijan R, Engelke K, Zwerina J, Englbrecht M, Schett G: Inflammatory bony spur formation in psoriatic arthritis is different from bony spur formation in hand osteoarthritis. Arthritis & rheumatology (Hoboken, NJ) 2014.

15.          Geusens P, Chapurlat R, Schett G, Ghasem-Zadeh A, Seeman E, de Jong J, van den Bergh J: High-resolution in vivo imaging of bone and joints: a window to microarchitecture. Nature reviews Rheumatology 2014, 10(5):304-313.

16.          Harre U, Kittan NA, Schett G: Autoantibody-mediated bone loss. Current osteoporosis reports 2014, 12(1):17-21.

17.          Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, Finzel S, Schett G: Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Annals of the rheumatic diseases 2014.

18.          Herz B, Albrecht A, Englbrecht M, Welsch GH, Uder M, Renner N, Schlechtweg P, Paul D, Lauer L, Engelke K et al: Osteitis and synovitis, but not bone erosion, is associated with proteoglycan loss and microstructure damage in the cartilage of patients with rheumatoid arthritis. Annals of the rheumatic diseases 2014, 73(6):1101-1106.

19.          Ipseiz N, Uderhardt S, Scholtysek C, Steffen M, Schabbauer G, Bozec A, Schett G, Kronke G: The nuclear receptor Nr4a1 mediates anti-inflammatory effects of apoptotic cells. Journal of immunology (Baltimore, Md : 1950) 2014, 192(10):4852-4858.

20.          Janko C, Filipovic M, Munoz LE, Schorn C, Schett G, Ivanovic-Burmazovic I, Herrmann M: Redox modulation of HMGB1-related signaling. Antioxidants & redox signaling 2014, 20(7):1075-1085.

21.          Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C et al: Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Annals of the rheumatic diseases 2014, 73(6):1020-1026.

22.          Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, Araujo E, Hueber AJ, Harre U, Engelke K et al: Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Annals of the rheumatic diseases 2014, 73(5):854-860.

23.          Kleyer A, Schett G: Arthritis and bone loss: a hen and egg story. Current opinion in rheumatology 2014, 26(1):80-84.

24.          Kocijan R, Finzel S, Englbrecht M, Engelke K, Rech J, Schett G: Decreased quantity and quality of the periarticular and nonperiarticular bone in patients with rheumatoid arthritis: a cross-sectional HR-pQCT study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2014, 29(4):1005-1014.

25.          Manger B, Schett G: Paraneoplastic syndromes in rheumatology. Nature reviews Rheumatology 2014.

26.          Manger B, Schett G: Palmar fasciitis and polyarthritis syndrome-Systematic literature review of 100 cases. Seminars in arthritis and rheumatism 2014, 44(1):105-111.

27.          Maueroder C, Munoz LE, Chaurio RA, Herrmann M, Schett G, Berens C: Tumor immunotherapy: lessons from autoimmunity. Frontiers in immunology 2014, 5:212.

28.          Maurer B, Graf N, Michel BA, Muller-Ladner U, Czirjak L, Denton CP, Tyndall A, Metzig C, Lanius V, Khanna D et al: Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Annals of the rheumatic diseases 2014.

29.          McGonagle D, Thomas RC, Schett G: Spondyloarthritis: may the force be with you? Annals of the rheumatic diseases 2014, 73(2):321-323.

30.          Museyko O, Marshall RP, Lu J, Hess A, Schett G, Amling M, Kalender WA, Engelke K: Registration of 2D histological sections with 3D micro-CT datasets from small animal vertebrae and tibiae. Computer methods in biomechanics and biomedical engineering 2014:1-16.

31.          Ossipova E, Cerqueira CF, Reed E, Kharlamova N, Israelsson L, Holmdahl R, Nandakumar KS, Engstrom M, Harre U, Schett G et al: Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint. Arthritis research & therapy 2014, 16(4):R167.

32.          Ruiz-Heiland G, Zhao Y, Derer A, Braun T, Engelke K, Neumann E, Mueller-Ladner U, Liu Y, Zwerina J, Schett G: Deletion of the receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia and bone damage in arthritis. Annals of the rheumatic diseases 2014, 73(4):771-779.

33.          Schauer C, Janko C, Munoz LE, Zhao Y, Kienhofer D, Frey B, Lell M, Manger B, Rech J, Naschberger E et al: Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nature medicine 2014, 20(5):511-517.

34.          Schett G: Bone formation in psoriatic arthritis: a report from the GRAPPA 2013 Annual Meeting. The Journal of rheumatology 2014, 41(6):1218-1219.

35.          Stadlmayr A, Aigner E, Huber-Schonauer U, Niederseer D, Zwerina J, Husar-Memmer E, Hohla F, Schett G, Patsch W, Datz C: Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta diabetologica 2014.

36.          Teufel S, Grotsch B, Luther J, Derer A, Schinke T, Amling M, Schett G, Mielenz D, David JP: Inhibition of bone remodeling in young mice by bisphosphonate displaces the plasma cell niche into the spleen. Journal of immunology (Baltimore, Md : 1950) 2014, 193(1):223-233.

37.          Timmen M, Hidding H, Wieskotter B, Baum W, Pap T, Raschke MJ, Schett G, Zwerina J, Stange R: Influence of antiTNF-alpha antibody treatment on fracture healing under chronic inflammation. BMC musculoskeletal disorders 2014, 15:184.

38.          Toh ML, Bonnefoy JY, Accart N, Cochin S, Pohle S, Haegel H, De Meyer M, Zemmour C, Preville X, Guillen C et al: A CSF-1 receptor monoclonal antibody has potent bone and cartilage protective effects in experimental arthritis. Arthritis & rheumatology (Hoboken, NJ) 2014.

39.          Tomcik M, Palumbo-Zerr K, Zerr P, Avouac J, Dees C, Sumova B, Distler A, Beyer C, Cerezo LA, Becvar R et al: S100A4 amplifies TGF-beta-induced fibroblast activation in systemic sclerosis. Annals of the rheumatic diseases 2014.

40.          Tomcik M, Zerr P, Pitkowski J, Palumbo-Zerr K, Avouac J, Distler O, Becvar R, Senolt L, Schett G, Distler JH: Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-beta signalling to prevent fibrosis. Annals of the rheumatic diseases 2014, 73(6):1215-1222.

41.          Topfer D, Finzel S, Museyko O, Schett G, Engelke K: Segmentation and quantification of bone erosions in high-resolution peripheral quantitative computed tomography datasets of the metacarpophalangeal joints of patients with rheumatoid arthritis. Rheumatology (Oxford, England) 2014, 53(1):65-71.

42.          Zerr P, Vollath S, Palumbo-Zerr K, Tomcik M, Huang J, Distler A, Beyer C, Dees C, Gela K, Distler O et al: Vitamin D receptor regulates TGF-beta signalling in systemic sclerosis. Annals of the rheumatic diseases 2014.

43.          Zhang Y, Dees C, Beyer C, Lin NY, Distler A, Zerr P, Palumbo K, Susok L, Kreuter A, Distler O et al: Inhibition of casein kinase II reduces TGFbeta induced fibroblast activation and ameliorates experimental fibrosis. Annals of the rheumatic diseases 2014.

44.          Zirngibl M, Furnrohr BG, Janko C, Munoz LE, Voll RE, Gregory CD, Schett G, Herrmann M: Loading of nuclear autoantigens prototypically recognized by SLE sera into late apoptotic vesicles requires intact microtubules and MLCK activity. Clinical and experimental immunology 2014.

Friday 5 September 2014

MRG Newcastle Publications Last Month

Another good month...

Mercedes O Chan, Ethan S Sen, Elizabeth Hardy, Pauline Hensman, Edmond Wraith, Simon Jones, Tim Rapley and Helen E Foster. Assessment of musculoskeletal abnormalities in children with mucopolysaccharidoses using pGALS. Paediatric Rheumatology 2014 12:32


Simon S Jameson, Kenneth S Rankin, Nicola L Desira, Philip James, Scott D Muller, Mike R Reed and Amar Rangan. Pulmonary embolism following ankle fractures treated without an operation – An analysis using National Health Service data.  Injury. Int. J. Care Injured 45 (2014) 1256-1261.


Rebecca Batten and Wan-Fai Ng.  Facial nerve compression by the posterior inferior cerebellar artery causing facial pain and swelling: a case report.  Journal of Medical Case Reports 2014 8:105


Katie L Hackett, Julia L Newton, Katherine H O Deane, Tim Rapley, Vincent Deary, Niina Kolehmainen, Dennis Lendrem, Wan-Fai.  Developing a service user informed intervention to improve participation and ability to perform daily activities in primary Sjögren's syndrome: a mixed-methods study protocol. BMJ Open (2014) 4 1-7.


Reynard LN, Bui C, Syddall CM, Loughlin J (2014) CpG methylation regulates allelic expression of GDF5 by modulating binding of SP1 and SP3 repressor proteins to the osteoarthritis SNP rs143383. Human Genetics 133:1059-1073.


Gee FH, Clubbs CF, Raine EVA, Reynard LN, Loughlin J (2014) Allelic expression analysis of the osteoarthritis susceptibility locus that maps to chromosome 3p21 reveals cis-acting eQTLs at GNL3 and SPCS1. BMC Medical Genetics 15:53.


Rushton MD, Reynard LN, Barter MJ, Refaie R, Rankin KS, Young DA, Loughlin J (2014) Characterization of the cartilage DNA methylome in knee and hip osteoarthritis. Arthritis Rheumatology 66:2450-2460.


Raine EVA, Reynard LN, van de Larr IMBH, Bertoli-Avella AM, Loughlin J (2014) Identification and analysis of a SMAD3 cis-acting eQTL operating in primary osteoarthritis and in the aortic aneurysms and early-onset OA syndrome. Osteoarthritis Cartilage 22:698-705.


Ratnayake M, Plöger F, Santibanez-Koref M, Loughlin J (2014) Human chondrocytes respond discordantly to the protein encoded by the osteoarthritis susceptibility gene GDF5. PLoS ONE 9:e86590.


Rodriguez-Fontenla C, Calaza M, Evangelou E, Valdes AM, Arden N, Blanco FJ, Carr A, Chapman K, Deloukas P, Doherty M, Esko T, Garces CM, Gomez-Reino JJ, Helgadottir H, Hofman A, Jonsdottir I, Kerkhof HJM, Kloppenburg M, McCaskie A, Ntzani EE, Ollier WER, Oreiro N, Panoutsopoulou K, Ralston SH, Ramos YF, Riancho JA, Rivadeneira F, Slagboom PE, Styrkarsdottir U, Thorsteinsdottir U, Thorleifsson G, Tsezou A, Uitterlinden AG, Wallis GA, Wilkinson JM, Zhai G, Zhu Y, arcOGEN Consortium, Felson DT, Ioannidis JPA, Loughlin J, Metspalu A, Meulenbelt I, Stefansson K, van Meurs JB, Zeggini E, Spector TD, Gonzalez A (2014) Assessment of osteoarthritis candidate genes in a meta-analysis of 9 genome-wide association scans. Arthritis Rheumatology 66:940-949.

Louise Reynard: Osteoarthritis and the NCOA3 Gene

Congratulations to Louise Reynard who has received her first ARUK grant as PI. 

"Functional analysis of the osteoarthritis susceptibility locus residing at the nuclear receptor coactivator 3 gene NCOA3".  

£171,000 2014-2017. 

Wednesday 3 September 2014